

## BlueStar Genomic Health Care Index

The BlueStar Genomic Health Care Index (BDNANTR) tracks the performance of the largest and most liquid companies in the global genomic healthcare industry. This is a modified market cap-weighted index, and only includes companies that generate at least 50% of their revenue from health care therapies based on targeting or the modification of the genetic makeup of cells or uses mRNA, technology platforms that enable the development of genetics-based health care therapies, or laboratory equipment or services used to test, code, or develop genetics-based health care companies.

### Key Features



All Time High/Low      52-Week High/Low

Total Return Net Index      381.50/69.17      381.50/224.94

#### Size and Liquidity Requirements

Float-adjusted market capitalization of at least 300 mIn USD. Six-month average-daily-value-traded of at least 200000 USD.

#### Universe

Companies developing or producing gene-based healthcare technologies and therapies.

#### Diversification

Companies are liquidity weighted.

#### Review

Semi-annual in June and December.


### Index Data

| INDEX PARAMETERS |             | FUNDAMENTALS*         |        | ANNUALISED PERFORMANCE* |        |                 |        |
|------------------|-------------|-----------------------|--------|-------------------------|--------|-----------------|--------|
| Launch Date      | 22 May 2020 | Components            | 81     | Price/Earnings Trailing | -19.69 | 1 Month         | -7.03% |
| Type             | Sector      | Volatility (1 year)   | 34.84  | Price/Book              | 4.90   | 1 Year          | 16.95% |
| Currency         | USD         | Full MCap bn USD      | 631.01 | Price/Sales             | 15.82  | 3 Years         | 26.13% |
| Base Date        | 31 Dec 2015 | Float MCap bn USD     | 390.69 | Price/Cash Flow         | 32.26  | 5 Years         | 27.92% |
| Base Value       | 100.00      | Correlation* (1 year) | 0.59   | Dividend Yield          | 0.01   | Since Inception | 19.07% |

\* MSCI ACWI Biotechnology      \* as of 30 Sep 2021      \* Total Return Net Index

### Country and Size Weightings

| Country        | Count | Weight |
|----------------|-------|--------|
| United States  | 62    | 77.79% |
| United Kingdom | 4     | 5.54%  |
| Germany        | 3     | 3.72%  |
| China          | 2     | 2.22%  |
| France         | 2     | 2.08%  |
| Japan          | 2     | 1.94%  |
| New Zealand    | 1     | 1.60%  |
| Switzerland    | 1     | 1.14%  |
| Israel         | 1     | 1.09%  |
| Canada         | 1     | 1.01%  |
| Netherlands    | 1     | 0.98%  |
| Belgium        | 1     | 0.91%  |



■ US  
■ GB  
■ DE  
■ CN  
■ FR  
■ JP  
■ NZ  
■ CH  
■ IL  
■ CA  
■ NL  
■ BE



■ Large-Cap  
■ Mid-Cap  
■ Small-Cap  
■ Micro-Cap

| Size                        | Count | Weight |
|-----------------------------|-------|--------|
| Large-Cap (> 6 bn)          | 20    | 28.89% |
| Mid-Cap (1.5 bn - 6 bn)     | 26    | 34.49% |
| Small-Cap (0.2 bn - 1.5 bn) | 35    | 36.61% |
| Micro-Cap (0.0 bn - 0.2 bn) | 0     | 0.00%  |

## BlueStar Genomic Health Care Index

### Sector Weightings

| Sector      | Count | Weight  |
|-------------|-------|---------|
| Health Care | 81    | 100.00% |



### Index Components

| Top Components by Weight           |  | Country | Weight | Best Performing Components   |  | YTD     | 1 Day  |
|------------------------------------|--|---------|--------|------------------------------|--|---------|--------|
| INTELLIA THERAPEUTICS INC          |  | US      | 2.41%  | Ocugen, Inc.                 |  | 410.38% | 12.26% |
| MODERNA INC                        |  | US      | 2.31%  | Burning Rock Biotech Limited |  | -39.22% | 8.92%  |
| Codexis Inc                        |  | US      | 1.97%  | MODERNA INC                  |  | 234.60% | 7.05%  |
| ARCTURUS THERAPEUTICS HOLDINGS INC |  | US      | 1.90%  | BIONTECH SE                  |  | 261.78% | 5.96%  |
| MeiraGTx Holding plc               |  | GB      | 1.86%  | Sorrento Therapeutics, Inc.  |  | -0.07%  | 5.74%  |
| BIONTECH SE                        |  | DE      | 1.77%  |                              |  |         |        |
| ALNYLAM PHARMACEUTICALS INC        |  | US      | 1.75%  |                              |  |         |        |
| Veracyte Inc                       |  | US      | 1.75%  | Worst Performing Components  |  | YTD     | 1 Day  |
| Anavex Life Sciences Corporation   |  | US      | 1.70%  | Rubius Therapeutics, Inc.    |  | 104.08% | -4.50% |
| Oxford BioMedica Plc               |  | GB      | 1.69%  | Oxford BioMedica Plc         |  | 48.07%  | -2.97% |
| Pacific Edge Ltd                   |  | NZ      | 1.60%  | Epizyme Inc.                 |  | -59.12% | -2.42% |
| Praxis Precision Medicines, Inc.   |  | US      | 1.60%  | Sangamo Therapeutics, Inc    |  | -47.90% | -2.28% |
| <b>Subtotal</b>                    |  |         | 22.33% | CareDx Inc.                  |  | -2.75%  | -2.25% |

### Symbols

|                           | Symbol  | ISIN         | WKN    | Sedol   | Bloomberg | Reuters  | Telekurs |
|---------------------------|---------|--------------|--------|---------|-----------|----------|----------|
| <b>Price Index</b>        | -       | -            | -      | -       | -         | -        | -        |
| <b>Total Return Net</b>   | BDNANTR | DE000A3CLKA4 | A3CLKA | BLNPNQ5 | BDNANTR   | .BDNANTR | 57061641 |
| <b>Total Return Gross</b> | -       | -            | -      | -       | -         | -        | -        |

For further information visit [www.mvis-indices.com](http://www.mvis-indices.com)

Nothing on this factsheet shall be considered a solicitation to buy or an offer to sell a security, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of such jurisdiction. Neither MV Index Solutions GmbH nor any of its licensors makes any warranties or representations, express or implied, to the user with respect to any of the data contained herein. The data is provided for informational purposes only, and the Company shall not be responsible or liable for the accuracy, usefulness or availability of any information transmitted or made available through it. The MVIS® indices are protected through various intellectual property rights and unfair competition and misappropriation laws. In particular, Van Eck Associates Corporation has registered the "MVIS" trademark. You require a licence to launch any product whose performance is linked to the value of a particular MVIS® index and for all use of the MVIS® name or name of the MVIS® index in the marketing of the product. All information shown prior to the index launch date is simulated performance data created from backtesting ("simulated past performance"). Simulated past performance is not actual but hypothetical performance based on the same or fundamentally the same methodology that was in effect when the index was launched. Simulated past performance may materially differ from the actual performance. Actual or simulated past performance is no guarantee for future results.